C12Y 207/01112
Protein-tyrosine kinase
Official title: Protein-tyrosine kinase (2.7.1.112) (C12Y207/10001, C12Y207/10002 take precedence)
C12Y207/01112 (Protein-tyrosine kinase) appears on 8 US grants and 11 published applications in this corpus.
Search patents in C12Y- Granted patents
- 8
- Published applications
- 11
- Assignees
- 14
- Inventors
- 33
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 1 | 0 |
| 2017 | 1 | 2 |
| 2018 | 1 | 1 |
| 2019 | 1 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 2 |
| 2022 | 1 | 0 |
| 2023 | 0 | 0 |
| 2024 | 2 | 2 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for chimeric antigen receptor targeting cancer cells1 Sep 2026US 12,721,892 B2The University of North Carolina at Chapel Hill
- Tropomyosin receptor kinase (TRK) degradation compounds and methods of use30 Apr 2024US 11,969,472 B2Cullgen (Shanghai), Inc.
- Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such12 Mar 2024US 11,926,676 B2Crispr Therapeutics AG
- Protein inhibitors to complement and VEGF pathways and methods of use thereof6 Dec 2022US 11,518,984 B2AP Biosciences, Inc.
- Antibody-fynomer conjugates18 Jun 2019US 10,323,095 B2Mitsubishi Tanabe Pharma Corporation
- Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (ptk7) and immune cells expressing such24 Oct 2024US 2024/0352151 A1Crispr Therapeutics AG
- Methods and compositions for chimeric antigen receptor targeting cancer cells16 May 2024US 2024/0156864 A1The University of North Carolina at Chapel Hill
- Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (ptk7) and immune cells expressing such11 Nov 2021US 2021/0347913 A1Crispr Therapeutics AG
- Tropomyosin receptor kinase (trk) degradation compounds and methods of use14 Oct 2021US 2021/0315999 A1Cullgen (Shanghai), Inc.
- Ve-ptp knockout23 May 2019US 2019/0150413 A1Mannin Research Inc.
Most cited
By later US patents
- Protein inhibitors to complement and VEGF pathways and methods of use thereof7US 11,518,984 B2AP Biosciences, Inc. · 2022
- Protein inhibitors to complement and VEGF pathways and methods of use thereof6US 9,988,611 B2AP Biosciences, Inc. · 2018
- Pyrazole compounds and thiazole compounds as protein kinases inhibitors2US 9,255,072 B2National Health Rsearch Institutes · 2016
- Antibody-fynomer conjugates1US 10,323,095 B2Mitsubishi Tanabe Pharma Corporation · 2019